Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts

British Journal of Haematology

Volumn 155, Issue 5, 2011, Pages 636-638

  Castro, Oswaldo L ^a   Gordeuk, Victor R ^a   Gladwin, Mark T ^b   Steinberg, Martin H ^c  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Haemolysis; Sickle cell anaemia

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN S; HYDROXYUREA; LACTATE DEHYDROGENASE; PLACEBO; SENICAPOC; SILDENAFIL;

ALPHA THALASSEMIA; BLOOD VISCOSITY; CELL DENSITY; CLINICAL TRIAL; DRUG MECHANISM; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG ULCER; LETTER; PHENOTYPE; POLYMERIZATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SICKLE CELL ANEMIA;

ACETAMIDES; ANEMIA, SICKLE CELL; HEMOGLOBIN, SICKLE; HUMANS; PAIN; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRITYL COMPOUNDS;

EID: 81155131149     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08758.x     Document Type: Letter

References (10)

1. Ataga, K.I., Ballas, S.K., Yasin, C., Bigelow, C., St. James, L., Smith, W.R., Galacteros, F., Kutlar, A., Hull, J.H. & Stocker, J.W. (2011) Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). British Journal of Haematology, 153, 92-104.
2. Charache, S., Barton, F.B., Moore, R.D., Terrin, M.L., Steinberg, M.H., Dover, G.J., Ballas, S.K., McMahon, R.P., Castro, O. & Orringer, E.P. (1996) Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore), 75, 300-326.
3. Kato, G.J., Gladwin, M.T. & Steinberg, M.H. (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 21, 37-47.
4. Kinney, T.R., Helms, R.W., O'Branski, E.E., Ohene-Frempong, K., Wang, W., Daeschner, C., Vichinsky, E., Redding-Lallinger, R., Gee, B., Platt, O.S. & Ware, R.E. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood, 94, 1550-1554.
5. Machado, R.F., Barst, R.J., Yovetich, N.A., Hassell, K.L., Kato, G.J., Gordeuk, V.R., Gibbs, J.S.R., Little, J.A., Schraufnagel, D.E., Krishnamurti, L., Girgis, R.E., Morris, C.R., Berman Rosenzweig, E., Badesch, D.B., Lanzkron, S., Onyekwere, O., Castro, O.L., Sachdev, V., Waclawiw, M.A., Woolson, R., Goldsmith, J.C. & Gladwin, M.T. (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood [Epub ahead of print].
6. McNaughton-Smith, G.A., Burns, J.F., Stocker, J.W., Rigdon, G.C., Creech, C., Arrington, S., Shelton, T. & de Franceschi, L. (2008) Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. Journal of Medicinal Chemistry, 51, 976-982.
7. Schmidtko, A., Tegeder, I. & Geisslinger, G. (2009) No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends in Neurosciences, 32, 339-346.
8. Steinberg, M.H., Rosenstock, W., Coleman, M.B., Adams, J.G., Platica, O., Cedeno, M., Rieder, R.F., Wilson, J.T., Milner, P. & West, S. (1984) Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood, 63, 1353-1360.
9. Taylor VI, J.G., Nolan, V.G., Mendelsohn, L., Kato, G.J., Gladwin, M.T. & Steinberg, M.H. (2008) Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS ONE, 3, e2095.
10. Ware, R.E. (2010) How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, 115, 5300-5311.